Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin–unresponsive Carcinoma in Situ of the Bladder
Amanda A. Myers, Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Iakovos Toumazis(The University of Texas MD Anderson Cancer Center), Wassim Kassouf(McGill University), Hui Zhao(Shandong University of Traditional Chinese Medicine), Ruchika Talwar(Vanderbilt University Medical Center), J. Alfred Witjes(Radboud University Nijmegen), Patrick J. Hensley(University of Kentucky), Yair Lotan(Southwestern Medical Center), Sima P. Porten(City College of San Francisco), Roger Li(Unknown), Gary D. Steinberg(Rush University Medical Center), Stephen B. Williams(Cedars-Sinai Medical Center), Kelly K. Bree(The University of Texas MD Anderson Cancer Center), Amy N. Luckenbaugh(Vanderbilt University Medical Center), Andrea Necchi(Vita-Salute San Raffaele University), Vignesh T. Packiam(Rutgers, The State University of New Jersey), Neal D. Shore(Carolina Urologic Research Center), Bogdana Schmidt(University of Utah), Zhigang Duan(The University of Texas MD Anderson Cancer Center), Noah M. Hahn(Johns Hopkins University)
Cited by 8
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k